Hepatitis C Treatment Market to Reach US$12.7 Bn by 2032, Reports Persistence Market Research

The global hepatitis C treatment market continues to evolve rapidly as the introduction of curative direct-acting antivirals (DAAs) reshapes clinical practice, public health strategies, and commercial landscapes worldwide. According to recent industry assessments, the market is expected to be valued at US$9.8 billion in 2025 and grow steadily to US$12.7 billion by 2032, representing a CAGR of 3.8% throughout the forecast period. This growth trajectory reflects the combined impact of increasing diagnostic coverage, expansion of national elimination programs, and the widespread availability of highly effective pan-genotypic regimens that cure over 95% of treated patients.

Market expansion is strongly influenced by the rising adoption of short-course (8-12 week) therapies, streamlined testing-to-treatment pathways, and aggressive public procurement strategies in high-burden regions. Direct-acting antivirals continue to anchor global treatment protocols, capturing approximately 66.7% of total market value. Geographically, North America remains the leading region, holding 34.7% of global market share due to strong reimbursement frameworks and broad access to innovative therapies. Meanwhile, Asia Pacific emerges as the fastest-growing region, underpinned by rising generic drug production, expanded insurance coverage, and large eligible patient populations entering treatment programs.

Download Your Free Sample & Explore Key Insights: https://www.persistencemarketresearch.com/samples/3602

Key Highlights from the Report

• The global hepatitis C treatment market is projected to reach US$12.7 billion by 2032.
• Direct-acting antivirals account for 66.7% of total market value.
• North America leads with a 34.7% market share due to robust insurance coverage.
• Asia Pacific is the fastest-growing region driven by generic access and national screening programs.
• Pan-genotypic therapies represent 64.7% of the treated patient population.
• National elimination programs and large public tenders continue to expand treatment coverage.

Market Segmentation

The hepatitis C treatment market is segmented primarily by drug class, genotype, and the growing integration of diagnostics with therapeutics. Direct-acting antivirals form the dominant segment, reflecting widespread clinical preference for regimens that deliver sustained virologic response rates exceeding 95% with minimal adverse effects. These therapies are used across varied geographies and economic tiers, with branded products prevalent in high-income countries and generic versions enabling scaled treatment access in resource-limited settings.

From a genotype perspective, pan-genotypic regimens have transformed procurement and clinical decision-making by eliminating the need for genotype testing, a historically costly and time-consuming step. This broad-spectrum effectiveness supports national elimination efforts by simplifying clinical workflows and reducing logistical burdens. Their dominance is reinforced by streamlined regulatory approvals and strong inclusion in global treatment guidelines.

An emerging segmentation layer involves bundled diagnostics-and-treatment offerings, which are rapidly gaining traction. These integrated packages enable unified tenders that include rapid testing, digital tools for patient tracking, and fixed-dose combination DAAs. They are particularly popular in low- and middle-income countries aiming to scale test-and-treat strategies efficiently. Growth in this segment is also propelled by donor-backed programs and new mobile diagnostic platforms.

Regional Insights

North America continues to lead the global market, accounting for roughly 34.7% of total revenue. The region benefits from widespread adoption of branded DAAs, robust insurance coverage, and comprehensive screening programs targeting adult populations, high-risk groups, and underserved communities. State-led elimination initiatives in the United States are increasingly integrating telehealth models, community-based testing, and same-day prescribing workflows. These developments help sustain treatment volumes even as the prevalent pool declines.

Europe follows as the second-largest regional market, supported by centralized health systems, national treatment guidelines, and structured procurement mechanisms. Countries such as Germany, the U.K., France, Italy, and Spain demonstrate strong treatment penetration facilitated by consistent reimbursement and public-sector price negotiations. Enhanced screening integrated into sexual health and primary care settings continues to expand eligibility while improving the identification of acute cases.

Asia Pacific, however, stands out as the fastest-growing market due to its high disease burden, expanding diagnostic infrastructure, and dominance in global generic drug manufacturing. India's role as a supplier of low-cost DAAs supports large-scale treatment campaigns both domestically and internationally. China's improved reimbursement schemes, expanded coverage into rural areas, and rapid adoption of modern therapies contribute to sustained regional growth. Southeast Asian nations-including Indonesia and Vietnam-are ramping up nationwide screening and treatment access, supported by international partnerships and donor-funded public programs.

Get Custom Insights Designed for Your Business: https://www.persistencemarketresearch.com/request-customization/3602

Market Drivers

One of the most powerful drivers of market growth is the clinical effectiveness of modern direct-acting antivirals. These therapies have transformed hepatitis C treatment by offering short, well-tolerated regimens with cure rates above 95%. Their pan-genotypic availability simplifies treatment pathways and supports efficient test-and-treat models that reduce patient loss between diagnosis and therapy initiation. As global elimination goals intensify, countries are scaling national screening programs targeting high-risk populations, older adults, and underdiagnosed communities, thereby expanding the pool of patients eligible for treatment.

Public procurement programs also amplify market expansion by securing predictable multi-year demand. Large tenders supported by donor agencies and government budgets reduce affordability barriers and motivate manufacturers to maintain high-volume production capacity. Additionally, voluntary licensing agreements and widespread generic manufacturing have made therapies accessible to low-income regions, stimulating large-scale treatment campaigns that significantly increase overall treatment volumes.

Market Restraints

Despite encouraging trends, several key restraints continue to limit market growth. Most notably, the high cure rates of DAAs contribute to a shrinking prevalence pool in countries that adopted treatment early and at scale. As chronic infection rates decline, treatment initiations naturally decrease, leading to a long-term reduction in demand. This depletion effect is particularly pronounced in high-income countries where screening programs are well established and treatment access is widespread.

Pricing pressure presents another significant challenge. Originator drugs face intense competition from generic manufacturers, particularly in public tenders where price ceilings are strictly enforced. High-income markets continue to negotiate steep discounts for branded therapies, compressing revenue and profit margins. This environment pushes manufacturers to diversify portfolios geographically, invest in integrated service models, and develop new indications or shorter regimens to maintain competitive advantage.

Market Opportunities

Opportunities in the hepatitis C treatment market are increasingly centered around expanding diagnostic coverage and accelerating test-and-treat models. Many high-burden countries still struggle with low diagnosis rates, making point-of-care testing and mobile screening units essential to identifying new patients. When combined with digital linkage-to-care systems and integrated procurement for diagnostics and therapeutics, these expanded platforms create substantial growth potential for suppliers offering comprehensive treatment solutions.

Pediatric and acute hepatitis C indications represent another promising opportunity. Regulatory approvals enabling treatment in younger age groups expand the eligible patient base and support earlier intervention to prevent long-term complications. Rapid detection and shorter treatment durations have proven effective in limiting transmission within high-risk groups. Pediatric-focused programs are also gaining traction in maternal and child health systems, where introducing HCV screening and treatment creates new growth avenues for both branded and generic manufacturers.

Checkout Now & Download Complete Market Report: https://www.persistencemarketresearch.com/checkout/3602

Company Insights

• Gilead Sciences
• AbbVie
• Merck & Co.
• Bristol-Myers Squibb
• Cipla
• Mylan
• Dr. Reddy's Laboratories
• Zydus Lifesciences
• Hetero Healthcare
• Natco Pharma
• Roche
• Pfizer
• Johnson & Johnson
• Novartis
• Teva Pharmaceutical Industries
• Apotex
• Sun Pharmaceutical Industries
• Lupin
• Glenmark Pharmaceuticals
• Aurobindo Pharma

Market Segmentation

By Treatment Type

Direct-Acting Antivirals
Interferon-Based Therapies
Supportive/Adjunct Therapies
Diagnostics-Plus-Drug Packages

By Clinical Indication

Pan-Genotypic
Genotype-Specific
Acute
Chronic
Pediatric
Adult

By Distribution Channel

Public Health Programs & Tenders
Hospitals & Specialty Clinics
Primary Care & Decentralized Clinics
Retail Pharmacies

By Region

North America
Europe
East Asia
South Asia & Oceania
Latin America
Middle East & Africa

Recent Developments:

In June 2025, the U.S. FDA granted expanded approval for Mavyret (glecaprevir/pibrentasvir), making it the first 8-week oral therapy for acute hepatitis C in adults and children as young as three years old.

In the same month, Mavyret received Breakthrough Therapy Designation for acute HCV treatment, reinforcing its potential to accelerate global test-and-treat strategies.

Conclusion

The hepatitis C treatment market is positioned for steady long-term growth driven by highly effective antiviral therapies, robust public health initiatives, and expanded access made possible by generic manufacturing and voluntary licensing. While declining prevalence in high-income countries may reduce annual treatment volumes, the increasing detection of acute and pediatric cases, along with widespread test-and-treat adoption, ensures continued demand. Asia Pacific will remain the most dynamic growth region, while North America and Europe leverage structured clinical pathways and technology-enabled care models. As global elimination targets intensify, the market is expected to transition toward integrated diagnostic and therapeutic solutions that streamline care delivery and maximize programmatic impact.

Read More Related Reports:

US Assisted Living Facility Market https://www.persistencemarketresearch.com/market-research/us-assisted-living-facility-market.asp
US Assisted Reproductive Technology Market https://www.persistencemarketresearch.com/market-research/us-assisted-reproductive-technology-market.asp
Electronic Health Records Market https://www.persistencemarketresearch.com/market-research/electronic-health-records-market.asp
Chiropractic Care Market https://www.persistencemarketresearch.com/market-research/chiropractic-care-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.